NCT03386825View on ClinicalTrials.gov

Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib

CompletedOBSERVATIONAL

Enrollment

76

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

May 1, 2018

Study Completion Date

May 1, 2018

Conditions

Colorectal Neoplasms

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

Antineoplastic agents, protein kinase inhibitor (L01XE21)

Trial Locations (1)

Unknown

Belgium, Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY